JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2008, 57(6):254-259

Determination of metoprolol and its metabolite α-hydroxymetoprolol in serum by HPLC method with fluorescence detection

I. Peřinová*, J. Ďuricová, H. Brozmanová, I. Kacířová, M. Grundmann
Ostravská univerzita Ostrava, Ústav klinické farmakologie FN a Zdravotně-sociální fakulty

High-performance liquid chromatography method has been developed with a view of its future use in the phenotyping of CYP2D6 enzyme by metoprolol as a probe drug. Metoprolol, α-hydroxymetoprolol and the internal standard nadolol were extracted from serum with dichloromethane alkalinized with 1 mol/l NaOH. Chromatographic separations were performed on the reversed-phase column SupercosilTM LC-18 (15 cm × 3 mm, 5 μm) with the mobile phase containing acetonitril : methanol : water : triethylamine (15 : 5 : 80 : 0.1, pH 3.0) at a flow rate of 0.7 ml/min. Fluorescence detection (FL) was made at 230 nm (excitation) and 300 nm (emission). The total analysis time was 12 min. The retention time for α-hydroxymetoprolol, nadolol and metoprolol were 2.04, 3.02 and 9.04 min, respectively. The intra-assay and inter-assay precisions (coefficients of variation) were less than 7.2 %, and recovery values were found to be within 98.2-103.0 %. The calibration curve of the method was linear over a concentration range of 25-500 ng/ml (r = 0.999) for both compounds. The limit of detection was 5 ng/ml and the limit of quantification was 25 ng/ml for both metoprolol and α-hydroxymetoprolol. The reported method could be suitable for measurements of metoprolol and α-hydroxymetoprolol in serum from patients with hypertension, IHD and other illnesses.

Keywords: phenotyping CYP2D6; metoprolol; α-hydroxymetoprolol; HPLC-FL

Received: August 25, 2008; Accepted: October 10, 2008; Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Peřinová I, Ďuricová J, Brozmanová H, Kacířová I, Grundmann M. Determination of metoprolol and its metabolite α-hydroxymetoprolol in serum by HPLC method with fluorescence detection. Čes. slov. farm. 2008;57(6):254-259.
Download citation

References

  1. Fux, R., Mörike, K., Pröhmer, A. M. et al.: Clin. Pharmacol. Ther., 2005; 78, 378-387. Go to original source... Go to PubMed...
  2. Silas, J. H., Lennard, M. S., Tucker, G. T. et al.: Br. J. Clin. Pharmacol., 1984; 17,11-19. Go to original source... Go to PubMed...
  3. Duricová, J., Grundmann, M.: Ces. slov. Farm., 2007; 56, 220-224.
  4. Bodor, N., Buchwald, P.: AAPS J., 2005; 7, 820-833.
  5. Ismail, R., The, L. K.: J. Clin. Pharm. Ther., 2006; 31, 99-109. Go to original source... Go to PubMed...
  6. Godbillon, J., Duval, M.: J. Chromatogr., 1984; 309, 198-202. Go to original source... Go to PubMed...
  7. Chiu, F. C., Damani, L. A., Li, R. C., Tomlinson, B.: J. Chromatogr. B. Biomed. Sci. Appl., 1997; 696, 69-74. Go to original source... Go to PubMed...
  8. Fang, J., Semple, H. A., Song, J.: J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2004; 809, 9-14. Go to original source... Go to PubMed...
  9. Mistry, B., Leslie, J., Eddington, N. E.: J. Pharm. Biomed. Anal., 1998; 16, 1041-1049. Go to original source... Go to PubMed...
  10. Sohn, D. R., Kusaka, M., Shin, S. G. et al.: Ther. Drug. Monit., 1992; 14, 184-189. Go to original source... Go to PubMed...
  11. Li, G., Wang, R.: Chin. Med. J., 2006; 119, 2013-2017. Go to original source...
  12. Ramenskaya, G. V., Savchenko, A. Y., Agafonov, A. A. et al.: Bull. Exp. Biol. Med., 2002; 134, 159-160. Go to original source... Go to PubMed...
  13. Lecaillon, J. B., Godbillon, J., Abadie, F., Gosset, G.: J. Chromatogr., 1984; 305, 411-417. Go to original source... Go to PubMed...
  14. Goryachkina, K., Burbello, A., Boldueva, S. et al.: Eur. J. Clin. Pharmacol., 2008; 64, 275-282. Go to original source... Go to PubMed...
  15. Bramer, SL., Suri, A.: Clin. Pharmacokinet., 1999; 37, 41-51. Go to original source... Go to PubMed...
  16. Kirchheiner, J., Heesch, C., Bauer, S. et al.: Clin. Pharmacol. Ther., 2004; 76, 302-312. Go to original source... Go to PubMed...
  17. Rutledge, D. R., Garrick, C.: J. Chromatogr. Sci., 1989; 27, 561-565. Go to original source... Go to PubMed...
  18. Asimus, S., Elsherbiny, D., Hai, T. N. et al.: Fundam. Clin. Pharmacol., 2007; 21, 307-316. Go to original source... Go to PubMed...
  19. Mautz, D. S., Shen, D. D., Nelson, W. L.: Pharm. Res., 1995; 12, 2053-2056. Go to original source... Go to PubMed...
  20. Hoffmann, K. J., Gyllenhaal, O., Vessman, J.: Biomed. Environ. Mass. Spectrom., 1987; 14, 543-548. Go to original source... Go to PubMed...
  21. Rewiewer of Guidance. Validation of Chromatographic Methods. Center of Drug Evaluation and Research (CDER), CMC 3, 1994.
  22. Guidance for Industry. Q2B Validation of Analytical Procedures: Methodology. The International Conference on Harmonisation of Thechnical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 1996.
  23. Thompson, M., Ellison, S. L. R., Wood, R.: Pure Appl. Chem., 2002; 74, 835-855. Go to original source...
  24. Bievre, B. et al.: The Fitness for Purpose of Analytical Methods. A Laboratory Guide to Method Validation and Related Topics, EURACHEM Guide. 1998, s. 14.
  25. Brown, R., Caphart, M., Faustino, P. et al.: LCGC, 2001; 19, 74-79.
  26. Causon, R.: J. Chromatogr. B. Biomed. Sci. Appl., 1997; 689, 175-180. Go to original source... Go to PubMed...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.